Why Is TCR2 Therapeutics Stock Trading Higher Today?

TCR² Therapeutics TCRR shares are trading higher on Monday after the company and Adaptimmune Therapeutics ADAP announced an agreement under which the two companies will combine to create a cell therapy company focused on solid tumor treatment. 

Under the all-stock transaction, Adaptimmune shareholders will own 75% of the combined company and TCR² shareholders will own 25%.

Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics, said "The combination of our two companies not only sets the stage for near-term execution but also positions the new company for the longer-term. We jointly have an array of next-generation innovations that we will integrate to address the tumor micro-environment using both autologous and allogeneic approaches. Focus and specialization are critical in the cell therapy space and we believe the combined company has the technologies necessary to succeed. I am delighted that this combination provides a strong foundation to commercialize curative therapies for people with cancer."

TCR2 Therapeutics is a biotechnology company developing T cell hematologic cancer immunotherapies.

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients.

TCRR Price Action: TCR2 has a 52-week high of $3.88 and a 52-week low of $0.82.

TCR2 shares are up 31.6% at $1.59 at the time of writing, according to Benzinga Pro.

Market News and Data brought to you by Benzinga APIs
Posted In: Penny StocksMoverswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!